From cancer to differentiated cell

Learn more about our unprecedented approach,
from problem to our solution.

Glioblastoma

is the most common and aggressive malignant primary brain tumour.

40,000 new cases per year globally

GBM tumours are difficult to treat

Considered incurable

Nearly 100% of patients experience disease relapse after initial treatment

Current standard of care

is of limited benefit and prognosis is poor

Surgery, chemotherapy and Radiotherapy

There are 4 approved therapies which have had minimal impact on survival – TMZ the only therapy to demonstrate OS benefit (2.5 months)

Average survival after diagnosis is 15 months

Our solution: differentiation therapy

Paradigm shift in treating brain cancer

A platform technology leveraging neurobiology of brain stem cells to discover biological drugs that differentiate tumor cells,
particularly aggressive cancer stem cells.

Differentiation therapy turns cancer stem cells into “normal”, mature brain cells, thereby rendering them unable to multiply & in essence incapable of perpetuating the tumor

The strength of our approach

Distruptive discovery Platform

An unprecedented approach in the field of solid tissue cancers

Overcames flaws in drug discovery

responsible for repeated failures in neurocology

Unconventional

Pipeline of unconventional & innovative leads

A distruptive discovery and validation platform

icone-stemgen-05

Normal Human
Brain Stem Cell Lines

icone-stemgen-06

Brain Cancer Stem Cell
Primary Lines n=(60)

icone-stemgen-07

Surgery Tissue
Samples

Subtractive Analysis
Nth Differential Conditions

Defines new leads for differentiation, invasion, apoptosis, checkpoint inhibitors

icone-stemgen-08
1st Line Candidates
Stemness
icone-stemgen-09
1st Line Candidates
Invasion
icone-stemgen-10
1st Line Candidates
Check. Inhib.

Compound Libraries

Bioinformatics

Differential Display Data Integration

icone-stemgen-08
2nd Line Candidates
Stemness
icone-stemgen-09
2nd Line Candidates
Invasion
icone-stemgen-10
2nd Line Candidates
Check. Inhib.

Canonical screening

Interference candidates

Bioinformatics

Database Querying

Putative candidates

Golden Candidates

DISCOVERY MODULE

Our Platform is based on the largest collection of brain primary cancer and normal stem cell lines.

By proprietary assays it discovers and validates new leads that tackle specific cell functions in cancer-initiating cells with unprecedented, unmatched prediction ability